Moxibustion Exerts a Neuroprotective Effect through Antiferroptosis in Parkinson’s Disease

Juan Lu, Xuelei Liu, Ye Tian, Hang Li, Zhenxing Ren, Shuang Liang, Guiyu Zhang, Caiping Zhao, Xinrong Li, Tingting Wang, Dongfeng Chen, Weihong Kuang, Meiling ZhuEvidence-based 2019 · DOI

TL;DR

This study investigates the neuroprotective effects of moxibustion, a traditional Chinese medicine therapy, on a rat model of Parkinson's Disease (PD). Researchers found that moxibustion significantly improved motor behavior and protected dopaminergic neurons by suppressing ferroptosis, an iron-dependent form of cell death. This suggests moxibustion could be a promising complementary therapy for PD by targeting this specific cell death pathway.

What Problem Does This Paper Address?

Parkinson's Disease (PD) is a progressive neurodegenerative disorder characterized by the loss of dopaminergic neurons in the substantia nigra (SN). Current treatments primarily manage symptoms and do not halt or reverse neurodegeneration, often leading to significant side effects and a decline in quality of life. While the exact pathogenesis of PD is complex, iron accumulation in the SN has been implicated, contributing to a specific type of cell death known as ferroptosis. This paper addresses the need for novel therapeutic strategies that can protect these vulnerable neurons and slow disease progression, exploring the potential of moxibustion, a well-established traditional therapy, to mitigate PD pathology by targeting ferroptosis.

Methods

The researchers established a PD model in Sprague-Dawley rats using a stereotactic injection of 6-hydroxydopamine (6-OHDA) into the substantia nigra (SN) and ventral tegmental area. Moxibustion was applied to the Baihui (GV20) and Sishencong (EX-HN1) acupoints for 20 minutes, six times a week, for six weeks.

Key assessment methods included:

  • Behavioral Testing: Apomorphine-induced rotational behavior was used to assess motor deficits.
  • Histology: Hematoxylin and eosin (H&E) and Nissl's staining were employed to examine neuronal morphology and cell loss in the SN.
  • Immunohistochemistry: Tyrosine hydroxylase (TH) staining was used to quantify dopaminergic neurons.
  • RNA Sequencing (RNA-seq): This was used to identify differentially expressed genes (DEGs) in the SN and perform functional pathway analysis, specifically looking for enrichment in pathways related to ferroptosis.
  • Western Blot and RT-PCR: These techniques were used to measure the protein and mRNA expression levels of key ferroptosis regulators, specifically glutathione peroxidase 4 (GPX4) and ferritin heavy chain 1 (FTH1), as well as TH.

Datasets

Not discussed in the paper. The study utilized a rat model and collected tissue samples for analysis.

Key Insights and Ideas

  • Moxibustion as an Antiferroptosis Therapy: The most significant insight is that moxibustion appears to exert its neuroprotective effects in PD by actively suppressing ferroptosis. This moves beyond general anti-inflammatory or antioxidant mechanisms to a more specific cellular death pathway.
  • Ferroptosis's Role in PD: The RNA-seq analysis strongly implicates the ferroptosis pathway in the pathogenesis of PD in this model, highlighting it as a critical target for intervention.
  • Targeting Key Ferroptosis Regulators: The study identified that moxibustion treatment led to increased expression of GPX4 and FTH1 in the SN. GPX4 is a crucial antioxidant enzyme that inhibits ferroptosis, while FTH1 is an iron storage protein. Their upregulation suggests a mechanism for preventing iron overload and subsequent lipid peroxidation, hallmarks of ferroptosis.
  • Synergistic Effects: The combination of improved behavioral scores, increased TH-positive neurons (indicating dopaminergic neuron protection), and suppression of ferroptosis suggests a multi-faceted protective mechanism of moxibustion.

Key Results

  • Behavioral Improvement: Moxibustion treatment significantly reduced apomorphine-induced rotational behavior in PD rats compared to the untreated PD model group (P < 0.001).
  • Neuronal Protection: Histological analysis showed that moxibustion preserved the morphology and increased the number of dopaminergic neurons in the SN of PD rats.
  • Increased TH Expression: Immunohistochemistry and Western blot analysis revealed significantly higher TH immunoreactivity and protein expression in the moxibustion group compared to the PD model group (P < 0.05 for immunohistochemistry, P < 0.001 for Western blot).
  • Ferroptosis Pathway Involvement: RNA-seq analysis identified the ferroptosis pathway as significantly enriched among differentially expressed genes in PD rats.
  • Upregulation of Ferroptosis Inhibitors: Moxibustion treatment led to a significant increase in both protein and mRNA levels of GPX4 and FTH1 in the SN of PD rats (P < 0.001 for most comparisons).

Limitations and Future Work

  • Model Limitations: The study used a 6-OHDA-induced rat model, which, while common, may not fully recapitulate the complex, multifactorial nature of human PD.
  • Mechanism Specificity: While the study strongly implicates ferroptosis, further research could explore the precise molecular cascade through which moxibustion influences GPX4 and FTH1 expression.
  • Human Translation: The findings are based on animal models. Future work should focus on translating these findings to human clinical trials to assess the efficacy and safety of moxibustion for PD patients.
  • Long-term Effects: The study focused on a 6-week treatment period. Investigating the long-term effects of moxibustion on PD progression and its sustained impact on ferroptosis would be valuable.
  • Combination Therapies: The authors suggest that the complementary effects of moxibustion, particularly its ability to increase antioxidative capacity and regulate neuronal activity, warrant further investigation, potentially in combination with other therapeutic approaches.

Summary updated

Abstract

The objective of this study was to explore the neuroprotective effect of moxibustion on rats with Parkinson's disease (PD) and its mechanism. A Parkinson's disease model was established in rats using a two-point stereotactic 6-hydroxydopamine injection in the right substantia nigra (SN) and ventral tegmental area. The rats received moxibustion at the Baihui (GV20) and Sishencong (EX-HN1) acupoints for 20 minutes, six times a week, for 6 weeks. The right SN tissue was histologically and immunohistochemically examined. Differentially expressed genes (DEGs) were identified through RNA sequencing. In addition, the levels of tyrosine hydroxylase (TH), glutathione peroxidase 4 (GPX4), and ferritin heavy chain 1 (FTH1) in SN were measured. In comparison to the model group, the moxibustion group showed a significantly greater TH immunoreactivity and a higher behavioural score. In particular, moxibustion led to an increase in the number and morphological stability of SN neural cells. The functional pathway analysis showed that DEGs are closely related to the ferroptosis pathway. GPX4 and FTH1 in the SN were significantly overexpressed in the moxibustion-treated rats with PD. Moxibustion can effectively reduce the death of SN neurons, decrease the occurrence of ferroptosis, and increase the TH activity to protect the neurons in rats with PD. The protective mechanism may be associated with suppression of the ferroptosis.
BibTeX
@inproceedings{lu2019moxibustion,
  author = {Juan Lu and Xuelei Liu and Ye Tian and Hang Li and Zhenxing Ren and Shuang Liang and Guiyu Zhang and Caiping Zhao and Xinrong Li and Tingting Wang and Dongfeng Chen and Weihong Kuang and Meiling Zhu},
  title = {{Moxibustion Exerts a Neuroprotective Effect through Antiferroptosis in Parkinson’s Disease}},
  booktitle = {Evidence-based},
  year = {2019},
  doi = {10.1155/2019/2735492},
}
Figure